# CHARACTERIZING AGGRESSIVE GLIOMA COPY NUMBER SUBTYPES

> **NIH NIH K08** · UNIVERSITY OF WASHINGTON · 2020 · $256,230

## Abstract

PROJECT SUMMARY/ABSTRACT
This proposal describes a 5-year career development program in which the applicant’s ultimate goal is to become an
independent physician-scientist with a focused clinical practice in neuropathology and a research laboratory dedicated
to the study of diffuse gliomas. The proposed research project will capitalize on the expertise and resources available at
the University of Washington/Fred Hutchinson Cancer Research Center Cancer Consortium, which has a proven track
record of developing physician-scientists. Dr. Eric Holland, an expert in mouse models of glioma and cancer biology, will
serve as the applicant’s research mentor. Diffuse gliomas comprise the most common and malignant primary
intracranial neoplasms in adults. Furthermore, over the last several decades there has been little success in prolonging
the survival of patients with diffuse glioma, and there is yet to be effective targeted therapies. One proposed
mechanism for poor treatment response of diffuse glioma lies in the intra- and inter-tumoral molecular and cellular
heterogeneity that make up these tumors. Over the last 3 years, the applicant has worked in Dr. Holland’s laboratory to
address this molecular heterogeneity within glioma, specifically investigating the role of somatic copy number
alterations (SCNAs). Through copy number profiling across adult glioma cohorts, prognostic SCNA subtypes were defined
with clear differences in median survival and selection biases were found to exist in smaller cohorts, having implications
on clinical trial design and applicability to the general population. Along with these human biomarker projects, studies of
pre-clinical glioma mouse models have been underway to begin to elucidate genetic drivers associated with SCNAs in
glioma. One such study identified HOXA5 as being a driver of chromosome 7 gain in glioma, with HOXA5 driving an
aggressive glioma phenotype including mediating radioresistance in vivo. Combining the applicant’s previously published
work with other preliminary data, the underlying biology of SCNA subtypes will be addressed in the current proposal,
primarily through the construction of SCNA subtype glioma mouse models, which will be functionally characterized (Aim
1). Additionally, the organismal and cellular consequences of SCNA subtype-specific responses to standard therapy (Aim
2) as well as immunotherapy (Aim 3) will be characterized. Overall, the candidate’s background in human and animal
investigative and diagnostic neuropathology is well-suited for this mentored research project focused on characterizing
biological consequences of SCNAs in gliomas and may yield novel approaches for the treatment of this malignancy.
Importantly, the proposed research also establishes a model system for studying glioma-associated SCNAs and
associated driver genes in gliomagenesis, which will provide the applicant with the foundation for an independent
research program.

## Key facts

- **NIH application ID:** 10052071
- **Project number:** 1K08CA245037-01A1
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Patrick J. Cimino
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $256,230
- **Award type:** 1
- **Project period:** 2020-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10052071

## Citation

> US National Institutes of Health, RePORTER application 10052071, CHARACTERIZING AGGRESSIVE GLIOMA COPY NUMBER SUBTYPES (1K08CA245037-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10052071. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*